La vendita allo scoperto per AngioDynamics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di AngioDynamics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

AngioDynamics (NASDAQ:ANGO) Azioni, Report sulle vendite allo scoperto

ANGIODYNAMICS INC

AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Angold Resources Ltd Ordinary Shares

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Wednesday.
The Dow traded up 0.36% to 42,141.02 while the NASDAQ rose 0.90% to 17,607.06. The S&amp;P 500 also rose, gaining, 0.56% to 5,664.60.
Check This Out: <a href="https://www.benzinga.com/25/04/44604078/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 6% Dividend Yields</a>
Leading and Lagging Sectors Real estate shares rose by 0.1% on Wednesday.
In trading on Wednesday, information technology shares tumbled by 0.4%.
Top Headline
Private businesses in the U.S. added 155,000 jobs in March compared to a revised 84,000 gain in February and higher than market estimates of 105,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares shot up 207% to $1.52 after the company announced a distribution deal with a top national alcohol company to expand its reach in the US market.</li>
<li>Shares of AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>)got a boost, surging 9% to $10.55 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>ConnectM Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares were also up, gaining 123% to $1.1010 after the company announced it received a $1.60 per share buyout offer from 3 institutional investors.</li>
</ul>
Equities Trading DOWN
<ul>
<li>nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) shares dropped 24% to $21.50 after the company reported a fourth-quarter adjusted EPS miss. Additionally, Piper Sandler and Needham cut their respective price targets on the stock.</li>
<li>Shares of BingEx Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) were down 51% to $2.54.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) was down, falling 49% to $0.1392 after the company announced it will delist its shares from Nasdaq capital market.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $71.21 while gold traded up 0.9% at $3,175.50.
Silver traded up 0.8% to $34.57 on Wednesday, while copper rose 0.2% to $5.0435.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.99%, Germany's DAX 40 dipped 1.33% and France's CAC 40 fell 0.77%. Spain's IBEX 35 Index fell 0.11%, while London's FTSE 100 fell 0.68%.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.28%, China's Shanghai Composite Index gaining 0.05%, Hong Kong's Hang Seng Index falling 0.02% and India's BSE Sensex gaining 0.78%.
Economics
<ul>
<li>U.S. mortgage applications fell by 1.6% in the week ending March 28.</li>
<li>Private businesses in the U.S. added 155,000 jobs in March compared to a revised 84,000 gain in February and higher than market estimates of 105,000.</li>
<li>New orders for US manufactured goods rose by 0.6% month-over-month for February compared to a revised 1.8% gain in January.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ANGO

CNTM

NCNO

SYRA

Gold Moves Higher; US Private Sector Job Growth Tops Estimates

AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus for a per-share loss of 13 cents</a>.
The maker of medical Instruments and supplies reported sales of $72 million, up 9.2% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $70.3 million</a>.
Read Next: <a target="_blank" href="https://www.benzinga.com/25/04/44592342/apellis-pharmaceuticals-rare-kidney-disease-drug-under-fda-review-seeks-to-compete-novartis-recently-approved-drug" rel="noreferrer noopener">FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals</a>
Med Tech&#8217;s net sales were $31.3 million, up 22.2%, driven by strength across all product lines, including Auryon sales of $13.9 million, up 17.3%, AngioVac sales of $6.8 million, up 23.1%, AlphaVac sales of $3 million, up 161.4%, and NanoKnife disposable sales of $4.9 million, <a href="https://www.benzinga.com/pressreleases/25/04/b44602856/angiodynamics-reports-fiscal-year-2025-third-quarter-financial-results" target="_blank" rel="noreferrer noopener">which increased 16.2%</a>.
Med Device net sales were&nbsp;$40.7 million, almost flat year over year.
Gross margin for the third quarter of fiscal 2025 was 54.0%, up 290 basis points versus a year ago.
Adjusted EBITDA was $1.3 million, compared to a $3.6 million loss in the third quarter of fiscal 2024.
"As we look ahead, we are well positioned to deliver profitable growth going forward&#8230;With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets," said Jim Clemmer, president and CEO.
Guidance: AngioDynamics expects its fiscal-year 2025 net sales of $285 million to $288 million, representing growth of 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million, compared to prior guidance of $282 million—$288 million and a consensus of $284.91 million.
The outlook includes Med Tech net sales growth of 14% to 6%, compared with prior guidance of 12% to 15%. Med Device net sales are expected to be flat.
The gross margin is expected to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%
The company expects adjusted EBITDA of $4 to $5 million, an increase from prior guidance of $1 to $3 million, and compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of 31 cents to 34 cents, compared to prior loss guidance of 34 cents to 38 cents and consensus loss of 37 cents.
Price Action: ANGO stock is up 10.09% at $10.63 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/04/44592692/bwx-technologies-poised-for-growth-in-nuclear-power-medical-radioisotopes-says-analyst" target="_blank" rel="noreferrer noopener">BWX Technologies Poised For Growth In Nuclear Power, Medical Radioisotopes Says Analyst</a></li>
</ul>
Photo: Shutterstock/Pavel Kapysh

Guidance

Health Care

Movers

General

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.
Shares of Cognyte Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CGNT">fourth-quarter financial results</a>.
Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.
Cognyte Software shares jumped 22.1% to $10.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) gained 13.1% to $14.26.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares rose 12% to $41.99.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) shares surged 11.7% to $10.69.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 10.1% to $57.90.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) rose 9.8% to $7.04.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) surged 9.5% to $136.97.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 8.3% to $1.6250.</li>
<li>Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 7% to $3.85.</li>
<li>Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) gained 5.9% to $64.28.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares rose 4.6% to $64.34.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose 3.8% to $248.24 ahead of quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

ACLX

ALGT

CGNT

CIEN

COOP

CRWV

CYTK

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

WIIM

AngioDynamics shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 guidance above estimates.

AngioDynamics Expects 2025 Adjusted EPS Loss Of $(0.31)-$(0.34) Compared To Prior Guidance Of $(0.34)-$(0.38) And Consensus Of $(0.37)

Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
<ul>
<li>The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.</li>
<li>The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.</li>
<li>The Company continues to expect Med Device net sales to be flat.</li>
<li>The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.</li>
<li>The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024. &nbsp;</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Guidance Action</td>
<td colspan="1" rowspan="1">
Current Guidance
(As of Apr. 2, 2025)
</td>
<td colspan="1" rowspan="1">
Previous Guidance
(Issued on Jan. 8, 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$285 - $288 million</td>
<td colspan="1" rowspan="1">$282 - $288 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Tech Net Sales Growth</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">14 - 16%</td>
<td colspan="1" rowspan="1">12 - 15%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Device Net Sales Growth</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Flat (unchanged)</td>
<td colspan="1" rowspan="1">Flat</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">53 - 54%</td>
<td colspan="1" rowspan="1">52 - 53%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$4.0 - $5.0 million</td>
<td colspan="1" rowspan="1">$1.0 - $3.0 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">($0.31) - ($0.34)</td>
<td colspan="1" rowspan="1">($0.34) - ($0.38)</td>
</tr>
</tbody>
</table>
</figure>

AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.13) by 123.08 percent. This is a 118.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $72.00 million which beat the analyst consensus estimate of $70.30 million by 2.42 percent. This is a 4.23 percent decrease over sales of $75.18 million the same period last year.

Earnings Beats

AngioDynamics Q3 2025 Adj EPS $0.03 May Not Be Comparable To $(0.13) Estimate, Sales $72.00M Beat $70.30M Estimate

<h3>Companies Reporting Before The Bell</h3>
• BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $132.81 million. 
• Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $93.15 million. 
• AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) is expected to report quarterly loss at $0.13 per share on revenue of $70.30 million. 
• UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is projected to report quarterly earnings at $1.34 per share on revenue of $602.81 million. 
<h3>Companies Reporting After The Bell</h3>
• Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $79.62 million. 
• RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is expected to report quarterly earnings at $1.91 per share on revenue of $829.53 million. 
• Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is projected to report quarterly loss at $0.06 per share on revenue of $62.65 million. 
• ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) is projected to report earnings for its fourth quarter. 
• Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $344.66 million. 
• Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) is expected to report quarterly loss at $0.10 per share on revenue of $130.00 million. 
• Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) is likely to report earnings for its Fiscal Year 2024. 
• EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) is projected to report earnings for its fourth quarter. 
• Logistic Properties (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LPA#AMEX">LPA</a>) is estimated to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSET

CLIR

EXOZ

NBTX

Penguin Solutions, Inc. - Ordinary Shares

PENG

Earnings Scheduled For April 2, 2025

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-02. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect AngioDynamics to report an earnings per share (EPS) of $-0.11.
AngioDynamics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.07, leading to a 0.0% drop in the share price the following trading session.
Here's a look at AngioDynamics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.16</td>
<td>-0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.11</td>
<td>-0.06</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>38.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743516050_0.png" alt="eps graph" />
<h3>Performance of AngioDynamics Shares</h3>
Shares of AngioDynamics were trading at $9.39 as of March 31. Over the last 52-week period, shares are up 51.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on AngioDynamics</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on AngioDynamics.
A total of 1 analyst ratings have been received for AngioDynamics, with the consensus rating being Buy. The average one-year price target stands at $15.0, suggesting a potential 59.74% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of NeuroPace, Semler Scientific and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for NeuroPace, with an average 1-year price target of $18.0, indicating a potential 91.69% upside.</li>
<li>Analysts currently favor an Buy trajectory for Semler Scientific, with an average 1-year price target of $71.0, suggesting a potential 656.12% upside.</li>
<li>Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $22.33, suggesting a potential 137.81% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for NeuroPace, Semler Scientific and Delcath Systems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-7.88%</td>
<td>$39.91M</td>
<td>-5.60%</td>
</tr>
<tr>
<td>NeuroPace</td>
<td>Outperform</td>
<td>19.18%</td>
<td>$16.19M</td>
<td>-58.87%</td>
</tr>
<tr>
<td>Semler Scientific</td>
<td>Buy</td>
<td>-17.56%</td>
<td>$11.31M</td>
<td>18.48%</td>
</tr>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>2701.48%</td>
<td>$12.97M</td>
<td>-8.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AngioDynamics ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, AngioDynamics is at the bottom compared to its peers.
<h3>Get to Know AngioDynamics Better</h3>
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
<h3>AngioDynamics: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, AngioDynamics faced challenges, resulting in a decline of approximately -7.88% in revenue growth as of 30 November, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AngioDynamics's net margin is impressive, surpassing industry averages. With a net margin of -14.74%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AngioDynamics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AngioDynamics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: AngioDynamics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ANGO/earnings">To track all earnings releases for AngioDynamics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: AngioDynamics's Earnings Preview

<h3>Gainers</h3>
<ul>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares rose 20.9% to $7.46 during Thursday's pre-market session. The company's market cap stands at $61.5 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock rose 18.09% to $2.48. The company's market cap stands at $104.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 17.69% to $12.44. The market value of their outstanding shares is at $37.8 million. </li>
<li>MeiraGTx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) shares increased by 14.04% to $7.31. The company's market cap stands at $571.3 million. </li>
<li>Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) stock rose 12.33% to $4.2. The market value of their outstanding shares is at $811.8 million. As per the news, the Q4 earnings report came out today. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock increased by 11.39% to $13.0. The market value of their outstanding shares is at $1.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock decreased by 26.5% to $3.61 during Thursday's pre-market session. The company's market cap stands at $161.6 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock decreased by 24.81% to $0.71. The market value of their outstanding shares is at $1.4 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares declined by 21.32% to $0.04. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 17.37% to $0.14. The market value of their outstanding shares is at $2.0 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) stock declined by 15.39% to $11.0. The market value of their outstanding shares is at $73.2 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares decreased by 12.66% to $8.21. The market value of their outstanding shares is at $332.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

AVAH

CRVO

ECOR

HEPA

HURA

MGTX

ONCO

XCUR

YMAB

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Thursday.
Shares of UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) fell sharply in today's pre-market trading after the company reported a fourth-quarter revenue miss and issued first-quarter revenue <a href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance">guidance below estimates</a>.
UiPath reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue of $424 million missed the analyst consensus estimate of $425.36 million and is an increase over revenue of $405.25 million from the same period last year.
UiPath shares dipped 16.7% to $9.85 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) fell 13.6% to $16.68 in pre-market trading after the company reported fourth-quarter results.      </li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) shares dipped 10.9% to $10.20 in pre-market trading following fourth-quarter results.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) fell 10.4% to $17.51 in pre-market trading after the company announced $200 million convertible senior notes offering.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) dipped 10.2% to $9.88 in pre-market trading as the company announced a proposed offering of convertible senior notes.</li>
<li>AnaptysBio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares tumbled 6.8% to $16.50 in pre-market trading.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 5.2% to $97.00 in pre-market trading.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) fell 3.2% to $9.10 in pre-market trading.</li>
<li>Mister Car Wash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NASDAQ">MCW</a>) fell 2.3% to $7.60 in pre-market trading. Raymond James analyst Bobby Griffin initiated coverage on Mister Car Wash with an Outperform rating and announced a price target of $10.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Pre-Market Outlook

ANAB

ATEN

PATH

PCAR

VNET

UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AngioDynamics Says It Initiated AMBITION BTK RCT And Registry To Advance Treatment For Critical Limb Ischemia

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment.
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography &amp; Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thrombectomy in Patients with Acute Pulmonary Embolism: Results from the Prospective APEX-AV Trial," was published December 27, 2024.
Pulmonary embolism (PE), a potentially life-threatening condition, affects approximately 900,000 individuals annually in the United States, with 10-30% of cases resulting in death within one month of diagnosis, according to the American Lung Association.1
The primary efficacy endpoint of the APEX-AV trial was the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint was the rate of MAEs, including events such as major bleeding and serious device-related clinical deterioration, pulmonary vascular injury, and cardiac injury within the first 48 hours. Patients were followed for 30 days post-index procedure. The results demonstrated the device as a safe and effective treatment for acute intermediate-risk PE with a significant reduction in RV/LV ratio and clot burden with a low rate of adverse events.
The APEX-AV trial demonstrated a 35.5% reduction in clot burden (via the Modified Miller index score), comparing favorably to other mechanical aspiration devices on the market.2 The unique design features of the device, including its funnel tip, optional wireless navigation, and blood loss mitigation, contributed to clinically significant improvements in both safety and efficacy.

Biotech

AngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled "Novel Mechanical Aspiration Thrombectomy In Patients With Acute Pulmonary Embolism: Results From The Prospective APEX-AV Trial"

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $14 to $15.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $15

U.S. stocks traded slightly lower midway through trading, with the Dow Jones index falling around 0.1% on Wednesday.
The Dow traded down 0.05% to 42,507.21 while the NASDAQ dipped 0.14% to 19,461.93. The S&amp;P 500 also fell, dropping, 0.03% to 5,907.51.
Check This Out: <a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Materials shares rose by 0.1% on Wednesday.
In trading on Wednesday, utilities shares tumbled by 1%.
Top Headline
U.S. initial jobless claims fell by 10,000 to 201,000 in the week ending Jan. 4, recording the lowest level in eleven months and versus market estimates of 218,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sana Biotechnology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares shot up 193% to $4.8390 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Shares of Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>)got a boost, surging 141% to $2.6680 after the company announced it was awarded a US patent for its PTSD treatment titled &#8216;Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.&#8217;</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares were also up, gaining 29% to $12.11 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares dropped 65% to $3.13 after the company announced the pricing of a $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Shares of Jasper Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) were down 59% to $7.26. The company reported preliminary data from its BEACON Phase 1b/2a study.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) was down, falling 54% to $0.0529. XTI Aerospace priced $20 million offering of 363,636,364 shares of common stock at a price of $0.055 per share.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $73.50 while gold traded up 0.4% at $2,676.80.
Silver traded up 0.5% to $30.850 on Wednesday, while copper rose 1.2% to $4.2475.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.54%, Germany's DAX 40 fell 0.34% and France's CAC 40 dipped 1.1%. Spain's IBEX 35 Index fell 0.61%, while London's FTSE 100 slipped 0.24%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 0.26%, China's Shanghai Composite Index gaining 0.02%, Hong Kong's Hang Seng Index declining 0.86% and India's BSE Sensex falling 0.07%.
Economics
<ul>
<li>U.S. private businesses added 122,000 workers to their payrolls in December down from 146,000 in November and versus expectations of 140,000.</li>
<li>U.S. initial jobless claims fell by 10,000 to 201,000 in the week ending Jan. 4, recording the lowest level in eleven months and versus market estimates of 218,000.</li>
<li>The Energy Information Administration said U.S. crude inventories declined by 0.959 million barrels last week, compared to market estimates of a 0.6 million barrel decline</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

DATS

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

SILO

XTIA

Crude Oil Down 1%; US Weekly Jobless Claims Decline

U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday.
Shares of AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) rose sharply during Tuesday's session after posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/42862022/aar-shares-climb-on-better-than-expected-q2-results-details">second-quarter results.</a>
The company reported quarterly earnings of 90 cents per share, which beat the analyst consensus estimate of 84 cents. Quarterly revenue came in at $686.1 million, which beat the analyst consensus estimate of $654.18 million.
AAR shares jumped 9.6% to $67.67 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares jumped 249% to $5.77 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) gained 64% to $12.97 after the company announced it&#8217;s presenting initial Phase 1 data from its two dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) surged 25% to $11.74 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 17% to $3.5900 after the company announced a strategic collaboration with AMD.</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) surged 11.5% to $70.44 after Meta announced a test in Germany, France and the US that will allow buyers to browse eBay listings directly on Facebook Marketplace.</li>
<li>Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) gained 10.2% to $29.87 as the company agreed to sell SGK Brand Solutions.</li>
<li>Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose 8.6% to $5.72 after the company announced it secured CFIUS clearance regarding Rio Tinto&#8217;s proposed acquisition.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) gained 7.1% to $111.00 as the company posted better-than-expected results for its second quarter. The company said it set a quarterly record for total dozens sold and specialty dozens sold. It also announced a cash dividend of approximately $1.49 per share.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) rose 6.3% to $10.25.</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) gained 4.6% to $96.24 after the company announced it entered into a definitive deal to acquire Bold Medical.</li>
<li>UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) gained 3.7% to $212.25 following upbeat quarterly earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

ABSI

ADTN

ALTM

CALM

EBAY

MATW

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday

AngioDynamics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

AngioDynamics Expects 2025 Adjusted EPS Loss Of $0.34 to $0.38 Compared To Prior Guidance Of $0.38-$0.42 And Consensus Of $0.40

<ul>
<li>The Company now expects Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%</li>
<li>The Company now expects Med Device net sales to be flat, a decrease from 1% to 3%</li>
<li>The Company continues to expect Gross margin to be approximately 52% to 53%</li>
<li>The Company now expects Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0. The updated guidance compares to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024</li>
</ul>

AngioDynamics Continues To Expect 2025 Net Sales Of $282M-$288M, Representing Growth Of Between 4.2%–6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $283.86M

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. The company reported quarterly sales of $73.02 million which beat the analyst consensus estimate of $70.93 million by 2.93 percent. This is a 9.17 percent increase over sales of $66.88 million the same period last year.

AngioDynamics Q2 2025 Adj EPS $(0.04) Beats $(0.11) Estimate, Sales $73.02M Beat $70.93M Estimate

Press Releases

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Comments

AngioDynamics

Vendite allo scoperto

AngioDynamics (NASDAQ:ANGO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO